Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a biotechnology company. The Company is focused on the discovery, development and commercialization of anti-infective products. The Company’s products are the formulations of its compound, CD101, which is an echinocandin. Its products include CD101 intravenous (biafungin) and CD101 topical (topifungin). In addition, it owns an immunotherapy technology platform, Cloudbreak. The Company is also developing other candidates for the treatment of bacterial and viral infections. CD101 IV and CD101 topical are in early stage of preclinical development. The Company’s Cloudbreak development candidates includeC001 and C016. It has conducted preclinical studies to evaluate the tolerability, toxicity and pharmacokinetic profile of C001 in mice and guinea pigs. Cloudbreak development candidates have demonstrated preclinical proof-of-principle efficacy and safety in preclinical studies.
